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Abstract
Introduction: Current literature indicates that African Ameri-
can individuals are at increased risk of becoming infected with
the SARS-CoV-2 virus and suffer higher SARS-CoV-2-related
mortality rates. However, there is a lack of consensus as to
how the clinical outcomes of African American patients differ
from those of other groups. The objective of this study was to
define the clinical outcomes of African American and White
hospitalized patients with SARS-CoV-2 community-acquired
pneumonia (CAP) in Louisville, Kentucky.
Methods: This was a retrospective cohort study of hospi-
talized patients with SARS-CoV-2 CAP at eight hospitals in
Louisville, Kentucky. Severity of CAP at time of hospital-
ization was evaluated using the pneumonia severity index
(PSI), CURB-65 score, SARS-CoV-2 viral load, and the World
Health Organization severity score. The following thirteen
clinical outcomes were compared: discharge alive to home,
time to home discharge, admission to the ICU, length of ICU
stay, need for invasive mechanical ventilation (IMV), duration
of IMV, development of acute respiratory distress syndrome
(ARDS), development of septic shock, need for vasopressors,
development of cardiovascular events, time to cardiovascular
events, in-hospital mortality, and time to death.
Results: A total of 541 patients were eligible for this study,
343 White (63%) and 198 African American (37%). None of
the thirteen clinical outcomes were significantly different be-
tween the two groups.
Conclusion: This study indicates that African American and
White patients do not have different clinical outcomes after
the point of hospitalization due to SARS-CoV-2 CAP.
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Introduction
The disproportionate likelihood of SARS-CoV-2 infec-
tion for African American individuals is well docu-
mented; a recent systematic review of 15 cohort and
cross-sectional studies found that the odds of testing
positive for SARS-CoV-2 infection were 1.5–3.5 times
greater for African American than White individu-
als.[1] A systematic review and meta-analysis of eight
studies similarly found that the odds of infection were
twice as high for African American individuals.[2] The
disparity in infection odds may be explained by factors
external to hospitalization.
The mortality data collected in several areas of the
United States indicates that SARS-CoV-2-related mor-
tality occurs more often in African American pa-
tients, relative to the percentage of SARS-CoV-2-
related mortality in the local population.[3-5] Pro-
visional age-adjusted mortality data show that non-
Hispanic African Americans are more than twice as
likely to have died from COVID-19 in 2020 compared
to non-Hispanic White Americans (151.1 vs 72.5 per
100,000, respectively).[6] Little is known concerning the
health outcomes of African American patients com-
pared to White patients during hospitalization due to
COVID-19. Previous studies have found no statisti-
cally significant association between African American
identity and post-hospitalization mortality in patients
with SARS-CoV-2.[7-12] Only three of the cited stud-
ies examined outcomes other than mortality, finding
no statistically significant association between African
American identity and ICU admission [7, 8], invasive
mechanical ventilation [7, 8], or critical illness.[9] A
more exhaustive evaluation of clinical outcomes has
not yet been performed. To investigate the possibil-
ity of differences between African American and White
patients for outcomes beyond mortality, we performed
a study evaluating 13 clinical outcomes of hospitalized
African American and White patients with SARS-CoV-
2 community-acquired pneumonia (CAP) in the city of
Louisville, KY. These 13 outcomes have been examined
in the literature; however, to our knowledge, our study
is the first to compare all of them for African American
and White patients in a single study.[1, 2, 7, 12-15]
Methods
This was a retrospective cohort study of hospitalized
patients with SARS-CoV-2 CAP at eight hospitals in
Louisville, Kentucky. Patients were eligible for in-
clusion if they were hospitalized from March 3, 2020
through July 1, 2020 with a provider diagnosis of CAP
and were positive for SARS-CoV-2 by reverse transcrip-
tion polymerase chain reaction test. Only patients indi-
cated as ‘Caucasian,’ ‘White,’ or ‘White or Caucasian’
and patients indicated as ‘African American’ or ‘Black
or African American’ in the electronic health record
were included in the analysis. Hispanic patients were
not excluded. Patients who developed pneumonia af-
ter admission to the hospital (e.g. nosocomial infection)
were excluded from the study.
Patient demographic, medical history, exam findings
and laboratory values, and severity of CAP were com-
pared between groups. Severity of CAP at time of hos-
pitalization was compared using the pneumonia sever-
ity index (PSI), CURB-65 score, WHO severity scale cat-
egories [16], and SARS-CoV-2 viral load, using cycle
threshold (Ct) value of initial RT-PCR for SARS-CoV-2
as a surrogate marker.
The following 13 clinical outcomes were compared: (1)
discharge alive to home, (2) time to home discharge, (3)
admission to the ICU, (4) length of ICU stay, (5) need
for invasive mechanical ventilation (IMV), (6) duration
of IMV, (7) development of acute respiratory distress
syndrome (ARDS), (8) development of septic shock, (9)
need for vasopressors, (10) development of cardiovas-
cular events, (11) time to cardiovascular events, (12) in-
hospital mortality, and (13) time to death. Clinical out-
comes were collected from the electronic health record.
Time-to-event outcomes were continuous; all other out-
comes were dichotomous.
Patient characteristics were reported as median and in-
terquartile range (IQR) for continuous variables and
frequency and percentage for categorical variables.
Continuous variables were compared using Mann-
Whitney U tests, and categorical variables were com-
pared using Chi-squared tests of independence. Mul-
tivariable logistic regression was used to compare ICU
admission, need for IMV, development of cardiovascu-
lar events, and in-hospital mortality between groups,
adjusting for CURB-65 score, sex, histories of conges-
tive heart failure, obesity (Body Mass Index ≥ 30),
diabetes, renal disease, neoplastic disease, coronary
artery disease, cerebrovascular disease, hypertension,
and hypoxemia (PaO2/FiO2 < 200 or SpO2/FiO2 <
141 if blood gasses were not obtained). CURB-65 score
was chosen instead of age as it includes several lab-
oratory values in addition to advanced age. Clus-
ter robust standard errors, using hospitals as clusters,
was performed to account for within-hospital varia-
tion. Adjusted odds ratios and 95% confidence inter-
vals were reported. Time-to-event outcomes were com-
pared using Log-rank tests, with Kaplan-Meier curves
produced. Median survival time and 95% confidence
limits were reported. All analysis was performed us-
ing R version 3.6. P-values of less than 0.05 were con-
sidered statistically significant.
Results
A total of 700 hospitalized patients with a positive
SARS-CoV-2 infection were identified between March
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Table 1. Demographics, social, and medical history of the study population.
African American White P-value
(n=198) (n=343)
Demographics and social history
Age (median [IQR]) 62 [51, 72] 66 [52, 77] 0.050
Sex: Male (%) 90 (45) 159 (46) 0.910
Nursing home resident (%) 32 (16) 78 (23) 0.085
Former smoker (%) 55 (28) 105 (31) 0.550
Current smoker (%) 21 (11) 29 (8) 0.498
Alcohol or drug abuse (%) 19 (10) 33 (10) >0.999
Depression, anxiety or other mental health issues (%) 26 (13) 96 (28) <0.001
Medical history
Obesity (%) 121 (61) 152 (44) <0.001
Diabetes (%) 82 (41) 115 (34) 0.081
Renal Disease (%) 49 (25) 68 (20) 0.218
Congestive heart failure (%) 30 (15) 46 (13) 0.665
Coronary artery disease (%) 28 (14) 65 (19) 0.190
Cerebrovascular disease (%) 34 (17) 47 (14) 0.335
Asthma (%) 24 (12) 34 (10) 0.512
Neoplastic disease (active or within the last year) (%) 15 (8) 28 (8) 0.938
COPD (%) 31 (16) 62 (18) 0.548
Liver disease (non-cirrhotic) (%) 7 (4) 15 (4) 0.803
Cirrhosis (%) 3 (2) 5 (1) >0.999
Essential arterial hypertension (%) 133 (67) 183 (53) 0.002
Hyperlipidemia (%) 74 (37) 133 (39) 0.817
Prior myocardial infarction (%) 19 (10) 36 (10) 0.853
Atrial fibrillation (%) 11 (6) 48 (14) 0.004
Prior deep vein thrombosis (%) 15 (8) 19 (6) 0.449
Abbreviations: IQR, interquartile range; COPD, chronic obstructive pulmonary disease.
Table 2. Physical examination and laboratory findings of the study population.
African American White P-value
(n=198) (n=343)
Heart Rate (beats/min) 95 [84, 110] 94 [78, 111] 0.654
Respiratory Rate (breaths/min) 21 [18, 27] 21 [18, 26] 0.696
Systolic Blood Pressure (mmHg) 122 [107, 142] 122.00 [105, 141] 0.669
Diastolic Blood Pressure (mmHg) 68 [57, 83] 67 [55, 78] 0.145
Temperature (degrees C) 37.7 [37.1, 38.6] 37.6 [36.9, 38.4] 0.086
SpO2/FiO2 429 [326, 452] 394 [267, 448] 0.005
PaO2/FiO2 214 [130, 294] 257 [136, 363] 0.110
WBC x 1000 per uL 6.38 [4.77, 8.56] 6.28 [4.44, 9.27] 0.972
Neutrophils x 1000 per uL 4.39 [3.14, 6.82] 4.82 [3.00, 8.11] 0.164
Lymphocytes x 1000 per uL 1.10 [0.73, 1.46] 0.94 [0.67, 1.46] 0.222
Neutrophil / Lymphocyte 3.98 [2.63, 7.15] 4.82 [2.79, 8.12] 0.064
Hematocrit (%) 38.3 [34.3, 41.9] 38.8 [35.1, 42.6] 0.263
Glucose (mg/dL) 125 [105, 168] 122 [103, 167] 0.355
Blood urea nitrogen (mg/dL) 18 [12, 33] 19 [12, 30] 0.973
Creatinine (mg/dL) 1.22 [0.80, 1.90] 1.00 [0.70, 1.40] <0.001
Ferritin (ng/dL) 404 [209, 1041] 377 [155, 836] 0.183
Procalcitonin (ug/L) 0.19 [0.05, 0.59] 0.11 [0.05, 0.36] 0.074
Lactate (mmol/L) 1.40 [1.00, 1.95] 1.40 [1.10, 1.80] 0.816
D-Dimer (ng/mL) 851.00 [396.50, 1612.75] 710.00 [410.00, 1589.00] 0.360
IL-6 (pg/mL) 56.75 [29.85, 83.50] 70.30 [32.70, 174.50] 0.060
C-reactive protein (mg/L) 77.88 [35.37, 148.50] 79.91 [42.00, 180.50] 0.171
Abbreviations: WBC, white blood cell count; IL-6, interleukin-6.
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3, 2020 and July 1, 2020. Of these hospitalizations, 632
patients were identified as having SARS-CoV-2 CAP,
including 541 patients who met the criteria for inclu-
sion. Analyzed patients included 198 (37%) African
American and 343 (63%) White patients. Patient demo-
graphics, social and medical histories are summarized
in Table 1. Few differences were observed between
groups. Most notably, higher rates of mental health
issues (13% vs 28%; P < 0.001) and atrial fibrillation
(6% vs 14%; P = 0.001) were prevalent among White
patients. Higher prevalence of obesity (61% vs 44%;
P <0.001) and hypertension (67% vs 53%; P = 0.002)
was observed in African American patients. Physi-
cal exam and laboratory values, summarized in Table
2, were also similar; African American patients had
significantly increased creatinine and slightly higher
SpO2/FiO2 ratios compared to White patients, but
these increases were not considered clinically relevant.
Indices for pneumonia severity between groups are
summarized in Figure 1. Severity between African
American and White patients was not significantly dif-
ferent for PSI risk classifications (P=0.459), CURB-65
scores (P=0.387), initial viral load (P=0.186), and WHO
severity score criteria (P=0.855).
Crude rates of the 13 clinical outcomes are summarized
in Table 3. None of the thirteen clinical outcomes, in-
cluding the rate of mortality at discharge (the least fa-
vorable outcome) were statistically significantly differ-
ent. Time to event outcomes are visualized in Figures
2–6.
Adjusted analysis of need for ICU admission, need for
IMV, development of cardiovascular events, and in-
hospital mortality are visualized in Figures 7–10. Af-
ter adjustment, African American patients did not have
significantly different odds of experiencing any of these
outcomes compared to White patients.
Discussion
This study demonstrates that there are no statisti-
cally significant differences in clinical outcomes be-
tween African American and White patients hospital-
ized with SARS-CoV-2 CAP. To our knowledge, this is
the first evaluation using 13 different clinical outcomes
to determine whether African American patients fare
worse after hospitalization for SARS-CoV-2 infection
than White patients.
Our data support the concept that disparities be-
tween African American and White patients in rela-
tion to SARS-CoV-2 infection are caused by factors ex-
ternal to hospitalization. To our knowledge, there is
no pathophysiologic medical mechanism that would
cause African American and White patients to respond
differently to medical treatment for SARS-CoV-2 infec-
tion, and our data support this hypothesis. The in-
creased mortality documented in studies of African
American individuals compared to White individuals
with SARS-CoV-2 infection is most likely due to factors
external to hospitalization.
Our data are consistent with the findings of other stud-
ies. The population of Louisville is approximately
22% African American and 72% White [17], yet we
observed that 31% of SARS-CoV-2 pneumonia hospi-
talizations were African American patients and 54%
were White patients, indicating that African American
individuals are overrepresented among SARS-CoV-2
pneumonia hospitalizations compared to the general
population of Louisville. Our study is also consis-
tent with other studies that found no statistically sig-
nificant association between African American iden-
tity and post-hospitalization mortality.[7-12] Likewise,
African American identity was not associated with ICU
admission or IMV in our study, consistent with two
others.[7, 8] Our analysis further found no statistically
significant association between African American iden-
tity and length of hospital stay, length of ICU stay, du-
ration of IMV, development of ARDS, development of
septic shock, need for vasopressors, development of
cardiovascular events, time to cardiovascular events, or
time to death.
One important strength of our study is that the de-
mographic characteristics, socioeconomic characteris-
tics, and health behaviors of the population of the city
of Louisville are highly generalizable to the United
States.[18] Consequently, our findings may be gener-
alizable to hospitalized patients nationwide. The pa-
tients in our study were from all areas of Louisville,
and thus represented a wide range of socioeconomic
statuses. Additionally, the breadth of the clinical out-
comes analyzed in this study makes our conclusions
more reliable. By utilizing cluster robust standard er-
rors, we can be certain that modifications of care did
not affect our results.
One important limitation in scope is that we were un-
able to evaluate outcomes for patients that did not seek
hospitalization. Differences in outcomes may still ex-
ist between African American and White individuals
who are infected with SARS-CoV-2 but not hospital-
ized. Additionally, outcomes were only evaluated for
hospitalized patients during the acute phase of infec-
tion; outcomes for non-hospitalized patients and pa-
tients in the post-acute phase of SARS-CoV-2 infec-
tion and recovery were not evaluated or characterized.
Case and fatality rates for Louisville do not indicate
the number of patients who were hospitalized, mak-
ing immediate comparisons to available data a diffi-
cult endeavor. We obtained information on patients’
identities from the electronic health record indication
of ‘Caucasian,’ ‘White,’ or ‘White or Caucasian’ and
‘African American’ or ‘Black or African American.’ We
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Figure 1. Severity of disease at time of hospital admission based on CURB-65 score, pneumonia severity index, and viral load for African
American and White patients.
Table 3. Crude outcomes for African American and White patients.
African American White P-value
(n=198) (n=343)
Discharged home (%) 129 (65) 215 (63) 0.269
Days to home discharge∗ 5.00 [4.19-6.33] 5.29 [4.58-6.55] 0.684
ICU admission (%) 80 (40) 139 (41) >0.999
Days in ICU* 15.80 [10.01-25.80] 10.80 [8.96-15.10] 0.115
Mechanically ventilated (%) 53 (27) 86 (25) 0.740
Days ventilated∗ 16.10 [13.00-30.00] 12.10 [10.10-29.10] 0.315
ARDS (%) 48 (24) 77 (22) 0.711
Septic shock (%) 28 (14) 44 (13) 0.763
Vasopressor use (%) 41 (21) 63 (18) 0.581
Cardiovascular event (%)
Days to cardiovascular event∗ 0.82 [0.37-3.20] 2.32 [0.96-5.26] 0.432
In-hospital mortality/Hospice care (%) 35 (18) 76 (22) 0.257
Days to mortality/hospice care∗ 7.76 [5.17, 11.60] 9.72 [8.25-11.30] 0.684
Abbreviations: ICU, intensive care unit; ARDS, acute respiratory distress syndome.
∗ Data represented as median survival times with 95% confidence limits. Comparisons between
estimates were made using log-rank tests.
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Figure 2. Patients discharged home and time to discharge home for African American and White patients. P-values represent chi-squared and
log-rank tests.
Figure 3. Patients admitted to the ICU and time spent in the ICU by African American and White patients. P-values represent chi-squared and
log-rank tests.
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Figure 4. Patients requiring mechanical ventilation and time spent ventilated by African American and White patients. P-values represent
chi-squared and log-rank tests.
Figure 5. Patients experiencing cardiovascular events and time to first cardiovascular event for African American and White patients. P-values
represent chi-squared and log-rank tests.
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Figure 6. Patients experiencing in-hospital mortality and time to in-hospital mortality for African American and White patients. P-values represent
chi-squared and log-rank tests.
Figure 7. Multivariable logistic regression for admission to the ICU. African American patients were compared to White patients. All variables
shown were independent predictors.
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Figure 8. Multivariable logistic regression for mechanical ventilation. African American patients were compared to White patients. All variables
shown were independent predictors.
Figure 9. Multivariable logistic regression for development of cardiovascular events. African American patients were compared to White patients.
All variables shown were independent predictors.
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Figure 10. Multivariable logistic regression for in-hospital mortality. African American patients were compared to White patients. All variables
shown were independent predictors.
were not able to verify that this information was con-
sistently self-reported or concurred with the patients’
self-identified race, which is considered the gold stan-
dard.[19] Patients of other identities were not evalu-
ated, as we did not have enough patients to justify anal-
ysis. Future studies are needed to evaluate the clini-
cal outcomes of non-White and non–African American
groups, as well as outcomes in non-hospital settings.
Once patients are hospitalized, there is no statisti-
cally significant difference in clinical outcomes between
African American and White patients. Future research
on racial disparities in SARS-CoV-2 outcomes should
therefore focus primarily on social causes and preven-
tive measures prior to hospitalization.
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